Second Quarter 2002 Earnings Per Share Increase 27 Percent To 38 Cents
Total Product Sales Increase 30 Percent Driven by Launch of New
Neulasta Sales Reach $110 Million in Initial Quarter of Launch
Amgen Raises 2002 Earnings Per Share Guidance to Mid 20 Percent
Excluding Impact of the Immunex Acquisition
ENBREL 2003 Revenue Guidance Adjusted to Range of $1.2 - $1.4 Billion
Amgen Affirms Less than 5 Percent 2003 Dilution as a Result of Immunex
Acquisition on an As Adjusted Basis
Aranesp Approved to Treat Chemotherapy Induced Anemia
FOR IMMEDIATE RELEASE
THOUSAND OAKS, Calif., July 24, 2002 - Amgen
(Nasdaq: AMGN) today announced that earnings
per share increased 27 percent for the second quarter of 2002, to
38 cents from 30 cents for the second quarter of 2001.
Net income increased 28 percent, to $412 million
from $322 million for the second quarter of 2001. Total revenue
increased 27 percent to $1.2 billion in the second quarter.
Product Sales Performance and Expenses
Combined sales of NEUPOGEN (Filgrastim),
used to decrease the incidence of infection during many types of
cancer-related chemotherapy, and Neulasta (pegfilgrastim),
Amgen's new once-per-cycle product for decreasing infections, increased
39 percent, to $473 million from $340 million for NEUPOGEN alone
in the second quarter of 2001. NEUPOGEN sales were $363 million
for the second quarter, an increase of 7 percent over the same quarter
last year. Neulasta sales totaled $110 million during its first
quarter on the market. Amgen believes that sales for the filgrastim
franchise were primarily driven by demand and, to a lesser extent,
by customary wholesaler stocking, principally in support of the
The company also believes that worldwide demand
grew in the mid 20 percent range during the quarter. For the full
year 2002, Amgen expects the combined NEUPOGEN/Neulasta
growth rate to be in the mid-20 percent range versus the company's
previous guidance of mid-teens growth.
Combined sales of EPOGEN (Epoetin alfa),
Amgen's anemia therapy for patients on dialysis, and Aranesp
(darbepoetin alfa), its next-generation anemia treatment for patients
on cancer chemotherapy, dialysis or not yet requiring dialysis,
for the second quarter increased 21 percent to $626 million from
$518 million for the second quarter of 2001. Aranesp sales totaled
$56 million and were primarily demand driven. EPOGEN sales were
$570 million for the second quarter, an increase of 10 percent over
the same quarter last year. EPOGEN sales were primarily driven by
demand growth in the high single digits, and to a lesser extent,
by wholesaler inventory changes. For 2002, Amgen continues to expect
combined sales of EPOGEN and Aranesp to grow in the low 20 percent
range over combined 2001 sales.
Total product sales in the quarter were $1.1
billion, an increase of 30 percent over the same period last year.
Total product sales, excluding the contribution from incremental
Immunex sales, are expected to grow in the mid-20 percent range
in 2002 versus previous guidance of a low 20 percent range.
"The second quarter demonstrates the strength
of our core business and the opportunity to significantly grow our
revenue base through the contribution of our new products,"
said Kevin Sharer, Chairman and CEO. "I believe Amgen is in
a great position to continue to enjoy solid growth. We have a group
of blockbuster products that possess long patent lives, which are
well positioned in large, fast growing markets with key benefits
over their competition," Sharer said.
While the Immunex acquisition was not completed
during the quarter and, thus, second-quarter Immunex sales were
not included in the results for Amgen, the Company announced the
second quarter sales performance for the inflammation biologic ENBREL
(etanercept) and the anti-cancer agent NOVANTRONE (mitroxantrone
for injection concentrate). ENBREL sales in the second quarter were
$192 million, a decrease from $217 million in the first quarter.
This decrease was due to Immunex experiencing a brief period in
the second quarter where ENBREL was not available to fill patient
prescriptions, primarily due to variations in the production yields.
NOVANTRONE sales were $19 million in the second quarter. Amgen will
record the incremental sales of Immunex generated from the July
15 date of closing. ENBREL sales are expected to range between $350
million and $400 million, and NOVANTRONE sales are expected to range
between $35 million and $40 million for the 5 1/2 months remaining
in 2002. Amgen also adjusted expectations for ENBREL in 2003 with
a range of between $1.2 billion and $1.4 billion versus a previous
estimate of $1.6 billion.
Because of higher than expected synergies,
the company continues to estimate that the acquisition will result
in less than 5 percent dilution in 2003 on an as adjusted basis.
In terms of second-quarter expenses, R&D
expenses of $234 million were 12 percent higher than the second
quarter of 2001. SG&A expenses of $321 million were 42 percent
higher than the second quarter of 2001 as the company increased
support for the launches of Aranesp, Neulasta and Kineret
(anakinra). For the full year 2002, Amgen's effective corporate
tax rate is expected to be approximately 31 percent.
For 2002, EPS growth, excluding the impact
of the acquisition of Immunex and excluding non-recurring charges,
is expected to grow at a mid 20 percent rate versus previous guidance
of a low 20 percent rate.
Following the acquisition of Immunex and beginning
in the third quarter of 2002, in addition to reporting earnings
in accordance with generally accepted accounting principles, Amgen
will report earnings on an as adjusted basis.
The acquisition is expected to dilute 2002
earnings by less than 10 percent on an as adjusted basis.
Amgen computes "as adjusted" earnings
by making the following adjustments net of tax, related to the acquisition
of Immunex to net income reported in accordance with generally accepted
- Add back the one-time non-cash expense associated with writing
off acquired in-process research and development, which will be
incurred in the third quarter of 2002 and is currently estimated
to be approximately $2.4 billion.
- Add back on-going non-cash amortization of acquired identifiable
intangible assets, principally related to ENBREL. This charge
will be incurred over the useful life of the assets, currently estimated
to be 15 years, and is currently estimated to be approximately $260
million on an annual basis.
- Add back the cash compensation principally related to Immunex
short-term employee retention plan. Estimated to be approximately
$100 million, this cost will be substantially incurred over two
years subsequent to the date of acquisition.
- Add back other merger-related expenses directly resulting from
As previously announced, last week the U.S. Food and Drug Administration
(FDA) approved the use of Aranesp for its second major indication
-- the treatment of chemotherapy-induced anemia in patients with
non-myeloid malignancies. Aranesp was developed to effectively treat
anemia with less frequent dosing than the current standard of therapy.
In addition to today's announcement of second-quarter financial
results, the company also announced that it will hold a Business
Review Meeting on November 21, 2002 to discuss anticipated future
To view the balance sheets, please click here.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and more fully described in the Securities and Exchange Commission
reports filed by Amgen, including our most recent Form 10-Q. Amgen
conducts research in the biotechnology/pharmaceutical field where
movement from concept to product is uncertain; consequently, there
can be no guarantee that any particular product candidate will be
successful and become a commercial product.
Furthermore, our testing, pricing, marketing and other operations
are subject to extensive regulation by domestic and foreign government
regulatory authorities. In addition, sales of our products are affected
by reimbursement policies imposed by third party payors, including
governments, private insurance plans and managed care providers.
These government regulations and reimbursement policies may affect
the development, usage and pricing of our products.
In addition, while we routinely obtain patents for our products
and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
Also, we may not realize all of the anticipated benefits of the
merger, including synergies, cost savings, sales and growth opportunities.
Furthermore, the limits on our current supply ENBREL constrain
ENBREL sales and our sources of supply for ENBREL are limited and
dependent on third party manufacturers. Additionally, the adjustments
related to the merger are based on a preliminary allocation of the
purchase price and estimates of anticipated expenses, and the final
determination of such allocation and expenses may differ significantly.
Because forward-looking statements involve risks and uncertainties,
actual results may differ materially from current results expected
by Amgen. Amgen is providing this information as of July 24, 2002
and expressly disclaims any duty to update information contained
in this press release.
Amgen is a global biotechnology company that discovers, develops,
manufactures, and markets important human therapeutics based on advances
in cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
# # #